Difference between revisions of "ALK translocation renal cell carcinoma"
Jump to navigation
Jump to search
Line 11: | Line 11: | ||
*Mix of morphologies - including: | *Mix of morphologies - including: | ||
**[[Papillary renal cell carcinoma]].<ref name=pmid24255633/> | **[[Papillary renal cell carcinoma]].<ref name=pmid24255633/> | ||
**[[Renal cell carcinoma with rhabdoid morphology| | **[[Renal cell carcinoma with rhabdoid morphology|Rhabdoid change]].<ref name=pmid26017874>{{Cite journal | last1 = Kuroda | first1 = N. | last2 = Karashima | first2 = T. | last3 = Inoue | first3 = K. | last4 = Kasajima | first4 = A. | last5 = Ohe | first5 = C. | last6 = Kawakami | first6 = F. | last7 = Mikami | first7 = S. | last8 = Matsuura | first8 = K. | last9 = Moriyama | first9 = M. | title = Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. | journal = Pol J Pathol | volume = 66 | issue = 1 | pages = 3-8 | month = Mar | year = 2015 | doi = | PMID = 26017874 }}</ref> | ||
**Sarcomatoid change. | **Sarcomatoid change. | ||
**"[[Unclassified renal cell carcinoma]]". | **"[[Unclassified renal cell carcinoma]]". |
Revision as of 20:05, 4 April 2019
ALK translocation renal cell carcinoma, also ALK-rearranged renal cell carcinoma and ALK-positive renal cell carcinoma, is a proposed entity within the Vancouver modification of the 2004 WHO classification of renal neoplasia.[1]
General
- Extremely rare - 1 in 829 consecutively screened patients.[2]
- In 2016, less than 17 cases reported.[3]
- May be related to renal medullary carcinoma which is reported to have an ALK rearrangement - t(2;10)(p23;q22).[4]
- May respond to ALK inhibitors such as alectinib[5] or crizotinib.[3]
Microscopic
Features:
- Mix of morphologies - including:
- Papillary renal cell carcinoma.[2]
- Rhabdoid change.[6]
- Sarcomatoid change.
- "Unclassified renal cell carcinoma".
DDx:
- Papillary renal cell carcinoma - especially type 2.[2]
- Unclassified renal cell carcinoma
- Renal medullary carcinoma.
IHC
Features:[7]
- ALK +ve.
- PAX8 +ve.
- Vimentin +ve (diffuse).
- CK7 +ve (focal).
- SMARCB1 +ve.[citation needed]
See also
References
- ↑ Srigley, JR.; Delahunt, B.; Eble, JN.; Egevad, L.; Epstein, JI.; Grignon, D.; Hes, O.; Moch, H. et al. (Oct 2013). "The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.". Am J Surg Pathol 37 (10): 1469-89. doi:10.1097/PAS.0b013e318299f2d1. PMID 24025519.
- ↑ 2.0 2.1 2.2 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
- ↑ 3.0 3.1 Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
- ↑ Mariño-Enríquez, A.; Ou, WB.; Weldon, CB.; Fletcher, JA.; Pérez-Atayde, AR. (Mar 2011). "ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.". Genes Chromosomes Cancer 50 (3): 146-53. doi:10.1002/gcc.20839. PMID 21213368.
- ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
- ↑ Kuroda, N.; Karashima, T.; Inoue, K.; Kasajima, A.; Ohe, C.; Kawakami, F.; Mikami, S.; Matsuura, K. et al. (Mar 2015). "Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects.". Pol J Pathol 66 (1): 3-8. PMID 26017874.
- ↑ Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.